Citi Sees Positive Catalysts for Telix Pharmaceuticals

Dow Jones

07/15

2305 GMT - Telix Pharmaceuticals' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. "We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus," analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at "buy, high-risk." (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

July 14, 2026 19:06 ET (23:06 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2651748293"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651748293\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651748293?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 07:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651748293","market":"sh","top_or_hot":-1,"title":"Citi Sees Positive Catalysts for Telix Pharmaceuticals","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2305 GMT - <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 19:06 ET (23:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citi Sees Positive Catalysts for Telix Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCiti Sees Positive Catalysts for Telix Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-15 07:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2305 GMT - <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 19:06 ET (23:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651748293","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651748293","pubTimestamp":1784070360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2305 GMT - Telix Pharmaceuticals' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\"  Dow Jones NewswiresJuly 14, 2026 19:06 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK7067":"生物科技","TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"花旗看到 Telix Pharmaceuticals 的积极催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX":1.5,"TLX.AU":0.9},"content_text":"2305 GMT - Telix Pharmaceuticals' stock looks a good bet to outperform over the next month, suggests Citi. That's despite a 41% rise in its share price since the start of the year. \"We open a positive 30-day catalyst watch on Telix as we think 2Q delivery will be robust and potentially ahead of consensus,\" analyst Laura Sutcliffe says. Citi also sees support for Telix's stock as it approaches the potential resubmission of kidney-cancer imaging agent Zircaix and potential approval and launch of brain-cancer imaging agent Pixclara. It rates Telix at \"buy, high-risk.\" (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 14, 2026 19:06 ET (23:06 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}